Gossamer Bio PROSERA Trial Failure
Analysis based on 22 articles · First reported May 18, 2026 · Last updated Jun 01, 2026
The failure of Gossamer Bio's Phase 3 PROSERA study and the subsequent 80% stock price drop significantly impacted its market valuation and investor confidence. The ongoing securities fraud lawsuits by firms like Hagens Berman, Glancy Prongay & Murray, and The Law Offices of Frank R. Cruz create further uncertainty for Gossamer Bio and highlight the risks associated with pharmaceutical trial outcomes for investors in the biotechnology sector.
Gossamer Bio is facing multiple securities class action lawsuits after its Phase 3 PROSERA study for pulmonary arterial hypertension failed to meet its primary endpoint on February 23, 2026. This announcement caused an 80% drop in Gossamer Bio's stock price. Law firms including Hagens Berman, Glancy Prongay & Murray, and The Law Offices of Frank R. Cruz have filed lawsuits and are investigating allegations that Gossamer Bio made misleading statements about the trial design, patient recruitment, and site-level monitoring, particularly concerning Latin American sites where patients allegedly performed unusually well on placebo. Additionally, Gossamer Bio revealed on April 9, 2026, that it has not met the minimum share bid price required for continued listing on the Nasdaq Global Select Market since February 24, 2026.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard